A Review of the Symptomatic Management of Malignant Gliomas in Adults

Shah, Umang; Morrison, Tara

doi:10.6004/jnccn.2013.0057

Cited by 27 publications

(12 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other symptoms frequently occurring in patients with GBM are listed in Figure 2. For a review on specific management of GBM symptoms, the reader is referred to AANN, 2014; Davis & Stoiber, 2011; Lacy, Saadati, & Yu, 2012; Pruitt, 2015; and Shah & Morrison, 2013.…”

Section: Supportive Carementioning

confidence: 99%

Glioblastoma: Overview of Disease and Treatment

Davis¹

2016

CJON

958

711

View full text Add to dashboard Cite

Background Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults. Current treatment options at diagnosis are multimodal and include surgical resection, radiation, and chemotherapy. Significant advances in the understanding of the molecular pathology of GBM and associated cell signaling pathways have opened opportunities for new therapies for recurrent and newly diagnosed disease. Innovative treatments, such as tumor-treating fields (TTFields) and immunotherapy, give hope for enhanced survival. Objectives This article reviews the background, risks, common complications, and treatment options for GBM. Methods A brief review of GBM, treatment options, and a look at new therapies that have been approved for new and recurrent disease are included in this article. Findings Despite aggressive resection and combined modality adjuvant treatment, most GBMs recur. Treatments, such as TTFields, drugs to target molecular receptors, and immunotherapy, are promising new options.

show abstract

Section: Supportive Carementioning

confidence: 99%

Glioblastoma: Overview of Disease and Treatment

Davis¹

2016

CJON

958

711

View full text Add to dashboard Cite

show abstract

“…In spite of aggressive therapy in glioblastoma patients who were qualified for surgical resection and chemo-and radiotherapy, the median survival has not significantly changed in the past decade and rarely exceeds 1 year. In a majority of cases, patient therapy is limited only to cytoreduction and anti-edematous treatment (Shah & Morrison, 2013;Shahar et al, 2012). This is caused by a highly invasive tumour characteristics and the impossibility to perform a radical surgery due to the lack of distinct boundaries around the infiltration.…”

Section: Discussionmentioning

confidence: 99%

Antidepressant drugs can modify cytotoxic action of temozolomide

Bielecka

Obuchowicz

2016

Eur J Cancer Care

View full text Add to dashboard Cite

Cancer patients often require antidepressant treatment due to comorbid depressive disorder. However, recent studies have demonstrated that antidepressant drugs affect the efficacy of chemotherapy and promote progression of cancer. Apart from the main mood-improving effect, antidepressant drugs also produce analgesic, anxiolytic, hypnotic and pro-cognitive actions. Patients suffering from brain cancer constitute the greatest percentage of depressive cancer patients. However, vital safety and efficacy issues related to combined therapy with temozolomide, the first-line cytostatic in patients diagnosed with glioblastoma multiforme, and antidepressant drugs have yet to be addressed. The aim of the present studies was to evaluate the effect of three antidepressant drugs (imipramine, fluoxetine and tranylcypromine) on the cytotoxic efficacy of temozolomide on T98G cells, a human glioblastoma cell line. In our experiments, we used a complex experimental in vitro system to mimic the instability of a tumour's oxygen supply, thereby reproducing conditions that occur inside the tumour. The effect of the interaction between temozolomide and antidepressant drugs on viability, apoptosis and intensity of divisions of glioblastoma cells was evaluated under different oxygen conditions. The results of our studies demonstrated that imipramine and tranylcypromine reduced the cytotoxic efficacy of temozolomide under some oxygen conditions while fluoxetine did not demonstrate such effects.

show abstract

“…Brain edema crucially contributes to the clinical course and outcome of patients with gliomas (4) and has been confirmed in experimental settings with mice (5). One critical cytotoxic mechanism for edema formation has recently been identified with the glutamate transporter xCT at center stage (6).…”

Section: Introductionmentioning

confidence: 95%

“…Fan et al, 4 To evaluate the influence of xCT-induced and glutamate on brain tumor growth apart from edema, we investigated the vasculature found in gliomas and assessed xCT-dependent tumor angiogenesis. These analyses allowed us to unravel the role of excitatory amino acid glutamate in tumor vessels and angiogenesis.…”

Section: Introductionmentioning

confidence: 99%